InnoCan Pharma (XCNQ:INNO) EPS (Basic): C$-0.53 (TTM As of Mar. 2026)

What is InnoCan Pharma EPS (Basic)?

InnoCan Pharma XCNQ:INNO -5.17% 64 EPS (Basic) is C$-0.53 as of Mar. 2026. GuruFocus rates XCNQ:INNO with a GF Score™ of 64/100 and a GF Value™ of C$15.17 (Possible Value Trap). The stock has 2 warning signs investors should review.

InnoCan Pharma's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was C$-0.30. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.53.

InnoCan Pharma's EPS (Diluted) for the three months ended in Mar. 2026 was C$-0.30. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.53.

InnoCan Pharma's EPS without NRI for the three months ended in Mar. 2026 was C$-0.30. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -1.00.

During the past 3 years, the average EPS without NRI Growth Rate was 30.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 21.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, InnoCan Pharma's highest 3-Year average EPS without NRI Growth Rate was 30.00% per year. The lowest was -64.10% per year. And the median was 9.90% per year.

InnoCan Pharma (XCNQ:INNO) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

InnoCan Pharma EPS (Basic) Related Terms

InnoCan Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for InnoCan Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma EPS (Basic) Chart

InnoCan Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-4.16

-1.41

-1.74

-0.93

-0.35

InnoCan Pharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-0.19	-0.18	-0.49	0.44	-0.30

64GF Score

InnoCan Pharma Corp XCNQ:INNO

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

InnoCan Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

InnoCan Pharma's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.551	-	0)	/	4.477
	=	-0.35

InnoCan Pharma's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.334	-	0)	/	4.499
	=	-0.30

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.53

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of C$-0.53 mean?

InnoCan Pharma (XCNQ:INNO) has a EPS (Basic) of C$-0.53 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on InnoCan Pharma and its competitors.

Is InnoCan Pharma's EPS (Basic) too high?

InnoCan Pharma's current EPS (Basic) is C$-0.53. Overall, InnoCan Pharma has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does InnoCan Pharma's EPS (Basic) compare to PG and CL?

InnoCan Pharma's EPS (Basic) of C$-0.53 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Consumer Packaged Goods company?

A good EPS (Basic) depends on the Consumer Packaged Goods industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on InnoCan Pharma and its competitors. InnoCan Pharma's current EPS (Basic) is C$-0.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is InnoCan Pharma stock overvalued right now?

Based on GuruFocus' analysis, InnoCan Pharma (XCNQ:INNO) is currently considered Possible Value Trap. The stock's GF Value™ is C$15.17, compared to a current price of C$2.75 — trading 81.9% below its estimated fair value. The current EPS (Basic) is C$-0.53. InnoCan Pharma's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For InnoCan Pharma (XCNQ:INNO), the current EPS (Basic) is C$-0.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCan Pharma (XCNQ:INNO) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued. The current stock price of C$2.75 is trading 81.9% below its estimated GF Value™ of C$15.17. GuruFocus considers InnoCan Pharma to be Possible Value Trap.

Key valuation signals for XCNQ:INNO:

EPS (Basic): C$-0.53
GF Value™: C$15.17 vs. price of C$2.75 (81.9% below fair value)
GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the XCNQ:INNO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCan Pharma Business Description

Industry Consumer Defensive Consumer Packaged Goods

Comparable Companies XCNQ:CGII XCNQ:ZRO TSX:DII.A PG XPAR:OR LSE:ULVR CL BOM:500696 LSE:RKT KVUE KMB EL XTER:HEN3 CHD OSTO:ESSITY B XTER:BEI TSE:4452 BOM:531642 BOM:532424 CLX

Other Exchanges INNPF:USA IP40:Germany

Address 1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7

Website https://www.innocanpharma.com

InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.

64GF Score

Get the complete analysis for XCNQ:INNO

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$2.75

Price

C$15.17

GF Value

View XCNQ:INNO Analysis

See EPS (Basic) data for all stocks →